Recent research from IVIRMA has established that the likelihood of a euploid embryo transfer resulting in an ongoing pregnancy is approximately 65% (1). In the search for what causes the…
We just started a fresh, new year full of energy and new ideas. Our team is growing, and our reach is now even larger. With the merge of the new…
Within the framework of the 78th Congress of the American Society for Reproductive Medicine (ASRM) The study of the embryo after its devitrification prior to transfer by means of an…
IVIRMA ) innovation is one of the four pillars of IVIRMA Global, the world’s largest company exclusively devoted to human Assisted Reproduction Technology (ART). A reality that began to take shape in 2017, IVIRMA ) innovation strives to lead scientific research and technology development in reproductive medicine and ART, with the ultimate aim of improving patient care.
To redefine the present and shape the future, IVIRMA brings together innovative investigators from the Old and the New Continent, promotes refining research techniques and encourages sharing knowledge.
Scientific innovation, technological progress, educational commitment, and clinical expertise… with one common goal: Excellence in Patient Care.
